Levetiracetam (UCB-L059)

N.º de catálogoS1356 Lote:S135603

Imprimir

Datos técnicos

Fórmula

C8H14N2O2
Peso molecular 170.21 Número CAS 102767-28-2
Solubilidad (25°C)* In vitro DMSO 34 mg/mL (199.75 mM)
Water 34 mg/mL (199.75 mM)
Ethanol 34 mg/mL (199.75 mM)
In vivo (Agregue los solventes al producto individualmente y en orden.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
Saline

Validado por los laboratorios Selleck. Si necesita ajustes en esta formulación, póngase en contacto con nuestro equipo de ventas para pruebas personalizadas.

 30.000mg/ml (176.25mM) Taking the 1 mL working solution as an example, add 30 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results. 
* <1 mg/ml significa ligeramente soluble o insoluble.
* Tenga en cuenta que Selleck prueba la solubilidad de todos los compuestos internamente, y la solubilidad real puede diferir ligeramente de los valores publicados. Esto es normal y se debe a ligeras variaciones entre lotes.
* Envío a temperatura ambiente (Las pruebas de estabilidad demuestran que este producto se puede enviar sin medidas de refrigeración.)

Preparación de soluciones madre

Actividad biológica

Descripción Levetiracetam (UCB-L059, SIB-S1) es un medicamento anticonvulsivo utilizado para tratar la epilepsia y un agonista de los receptores muscarínicos de acetilcolina (mAChR). Este compuesto también modula el canal de calcio (Ca2+) dependiente de voltaje de tipo P/Q presináptico.
Objetivos
Calcium channel
In vitro Levetiracetam (UCB-L059) and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for its binding. This compound irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. It selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons. Levetiracetam also reverses the inhibitory effect of DMCM on GABA-elicited currents in hippocampal neurons.
In vivo Levetiracetam (UCB-L059) (17 mg/kg) produces a potent suppression of sound-induced clonic convulsions in mice, and this protective effect is significantly abolished by co-administration of the beta-carboline FG 7142. It exerts potent anticonvulsant activity against both focal and secondarily generalized seizures in fully amygdala-kindled rats, i.e. , a model of temporal lobe epilepsy. This compound (13 mg/kg, 27 mg/kg or 54 mg/kg, i.p.) dose-dependently suppresses the increase in seizure severity and duration induced by repeated amygdala stimulation. It has a relatively short half-life (about 2-3 hours) in rats. Levetiracetam (5.4 mg/kg to 96 mg/kg i.p.) dose-dependently inhibits both wild running and tonic-clonic convulsions in the audiogenic-seizure prone rat. It markedly suppresses spontaneous spike-and-wave discharge (SWD) but leaves the underlying EEG trace normal in the GAERS model of petit mal epilepsy.

Protocolo (de referencia)

Referencias

  • https://pubmed.ncbi.nlm.nih.gov/15917812/
  • https://pubmed.ncbi.nlm.nih.gov/11879381/
  • https://pubmed.ncbi.nlm.nih.gov/12086975/
  • https://pubmed.ncbi.nlm.nih.gov/9454787/
  • https://pubmed.ncbi.nlm.nih.gov/8991787/

Validación de productos por parte del cliente

Levetiracetam reduces DNA, synaptic, and neurite damage caused by Dox. (A) An example of cortical cultures pre-treated with 5 μ M Lev and then Dox (0.01 μ M, overnight), fixed and stained with antibodies against MAP2c. Scale bar is 20 μ m. (B) Cortical neurons at 28–32 DIV were pre-treated with 5 μ M Lev, and then a vehicle or with Dox (0.01 μ M for 3 days, or 0.1 μ M, overnight) was added. Neurons were fixed, and stained for MAP2c, synapsin, and with the Hoechst dye, and imaged. Note that red MAP2c staining also includes Dox

Datos de [ , , Sci Rep, 2016, 6:25705. ]

Selleck's Levetiracetam (UCB-L059) Ha sido citado por 11 Publicaciones

GABAergic neuron-to-glioma synapses in diffuse midline gliomas [ Nature, 2025, 1060-1068] PubMed: 39972132
Salivary gland tissue chip screening identifies candidate radioprotective drugs [ Communications Medicine, 2025, 420] PubMed: 41068535
Network Dysfunction Precedes Neurodegeneration in a dox-Regulatable TDP-43 Mouse Model of ALS-FTD [ The Journal of Neuroscience, 2025, e2297242025] PubMed: nan
Network Dysfunction Precedes Neurodegeneration in a dox-Regulatable TDP-43 Mouse Model of ALS-FTD [ The Journal of Neuroscience, 2025, e2297242025]
Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimers disease [ Frontiers in Neuroscience, 2024, 1336026] PubMed: 38014102
Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer's disease [ Front Neurosci, 2023, 17:1336026] PubMed: 38328556
Levetiracetam Modulates Brain Metabolic Networks and Transcriptomic Signatures in the 5XFAD Mouse Model of Alzheimer's disease [ bioRxiv, 2023, 2023.11.10.566574] PubMed: 38014102
Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL-AD preclinical testing core study [ Alzheimers Dement (N Y), 2022, 8(1):e12329] PubMed: 36016830
A Low Dose of Aripiprazole Has the Strongest Sensitization Effect Among 19 Repositioned Bipolar Drugs in P-gp-overexpressing Drug-resistant Cancer Cells [ Anticancer Res, 2021, 41(2):687-697] PubMed: 33517273
AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. [ PLoS One, 2019, 14(2):e0211644] PubMed: 30716120

POLÍTICA DE DEVOLUCIÓN
La Política de Devolución Incondicional de Selleck Chemical garantiza una experiencia de compra en línea fluida para nuestros clientes. Si no está satisfecho con su compra de alguna manera, puede devolver cualquier artículo(s) dentro de los 7 días posteriores a su recepción. En caso de problemas de calidad del producto, ya sean problemas relacionados con el protocolo o con el producto, puede devolver cualquier artículo(s) dentro de los 365 días a partir de la fecha de compra original. Siga las instrucciones a continuación al devolver productos.

ENVÍO Y ALMACENAMIENTO
Los productos Selleck se transportan a temperatura ambiente. Si recibe el producto a temperatura ambiente, tenga la seguridad de que el Departamento de Inspección de Calidad de Selleck ha realizado experimentos para verificar que la colocación a temperatura normal durante un mes no afectará la actividad biológica de los productos en polvo. Después de la recogida, guarde el producto de acuerdo con los requisitos descritos en la hoja de datos. La mayoría de los productos Selleck son estables en las condiciones recomendadas.

NO PARA USO HUMANO, DIAGNÓSTICO VETERINARIO O TERAPÉUTICO.